Study of Topical Imipramine and Amitriptyline for Reducing Sunlight-Induced Redness in Adults with Rosacea

What this Trial Is About

Rosacea is a common skin condition that causes easy blushing and redness, often worsened by sunlight exposure. Researchers are studying whether topical medications can reduce this sunlight-induced redness and irritation in people with rosacea. This Phase 2 trial aims to evaluate the effects of two topical drugs, imipramine and amitriptyline, on skin redness caused by ultraviolet B UVB light. Participants apply either 4% imipramine or 4% amitriptyline on a small area 2x2 cm of one cheek, while a vehicle control substance is applied on the other cheek. There are two experimental groups one receiving imipramine and vehicle, and the other receiving amitriptyline and vehicle. The treatments are applied directly to the skin, allowing comparison of redness on treated versus untreated areas. During the study, redness levels caused by UVB light will be measured at 10 minutes, 60 minutes, 120 minutes, and 24 hours after treatment application. Researchers will also monitor how well the skin tolerates each medication over these same time points. Participants may be monitored over several visits to assess skin reactions and medication effects. The trial is randomized and double-blind, ensuring unbiased evaluation of the treatments impact on sunlight-induced redness in rosacea.

Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea